President Donald Trump’s nominee to lead the Food and Drug Administration, Dr. Heidi Overton, appeared before the Senate Health, Education, Labor, and Pensions Committee to answer questions on her fitness for the role. Lawmakers focused on her plans for vaccines, the abortion pill mifepristone, and other regulatory shifts that have drawn scrutiny under the current administration. The hearing began at 10:30 a.m. EDT.
Overton, a physician and former domestic policy adviser, has spent most of her career working within Trump’s orbit or for conservative groups aligned with his agenda. Her background includes work at the America First Policy Institute and a White House fellowship during Trump’s first term. If confirmed, she would succeed Dr. Marty Makary, who resigned in May amid internal disputes and staff departures.
What the Left Is Saying
Progressive voices and some moderate Republicans have raised concerns about Overton’s alignment with Health Secretary Robert F. Kennedy Jr.’s initiatives, particularly regarding vaccine safety. Overton stood with President Trump and Kennedy in the Oval Office last month when they suggested that combination vaccines could contribute to autism, a claim not supported by mainstream scientific consensus.
Critics point to Overton’s previous writings as evidence of ideological rigidity. While at the America First Policy Institute, she criticized the Biden administration’s 2023 decision to allow mail delivery of mifepristone, referring to the practice as "chemical abortion on demand." She also authored a 2024 article about Minnesota Governor Tim Walz titled "Tim Walz Made Minnesota A 'Sanctuary' For Baby Killers And Child Mutilators," reflecting her critical stance on transgender care and abortion access.
What the Right Is Saying
Supporters of Overton’s nomination emphasize her medical background and alignment with the administration’s goal to reduce regulatory burdens. Overton worked on the revamped food pyramid and efforts to overhaul childhood vaccination schedules, initiatives championed by the White House as necessary updates to federal health guidance.
Conservative lawmakers, including Senate Health Committee Chairman Bill Cassidy, have expressed concern about specific policy positions but also find common ground on other issues. Cassidy, a physician from Louisiana, previously urged the FDA to restrict access to mifepristone, aligning with Overton’s past criticism of its broad availability. The nomination is supported by factions within the Republican party that prioritize stricter scrutiny of drug safety and vaccine mandates.
What the Numbers Show
The FDA employs approximately 16,000 staff members across U.S. and international locations. Since Trump took office, the agency has lost about 20% of its employees due to layoffs, buyouts, retirements, or resignations. Overton’s financial disclosure forms report no investments in health care or food companies, contrasting with previous nominees who had to divest such holdings. She reported $50,000 to $100,000 in student loans.
To advance, Overton needs a majority vote from the 21-member health committee, followed by a simple majority in the full Senate. Chairman Bill Cassidy has stated that Overton’s support for spacing out vaccinations is "almost disqualifying," though he and other Republicans may align with her on abortion restrictions. Moderate Republicans Senators Susan Collins of Maine and Lisa Murkowski of Alaska, who support federal abortion access, remain key swing votes.
The Bottom Line
Overton’s confirmation hinges on navigating deep divisions within the Senate regarding vaccine policy and abortion access. Her lack of experience running a large bureaucracy mirrors that of her predecessor, Dr. Marty Makary, whose tenure was marked by internal dysfunction and staff morale issues. The FDA’s upcoming decisions on mifepristone safety reviews, combination vaccine schedules, and e-cigarette regulations will be made under her leadership if confirmed, setting the course for federal health policy for the remainder of the administration.